Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
US Oncology Research
NSABP Foundation Inc
Alliance for Clinical Trials in Oncology
German Breast Group
Grupo Espanol de Investigacion del Cancer de Mama
Information provided by (Responsible Party):
AbbVie
ClinicalTrials.gov Identifier:
NCT02032277
First received: December 13, 2013
Last updated: November 7, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)